On October 8, 10x Genomics fell 5.15% in pre-market trading, trading at $72.21 per share with turnover of $102.69 million.

The company's announcement of a multi-project research collaboration with Fred Hutchinson Cancer Center did not bolster market confidence. The partnership will use Flex Apex and Xenium platforms to identify treatment response biomarkers in advanced bladder cancer and assess single-cell analysis for residual disease detection in acute myeloid leukemia, but the news failed to offset prevailing negative sentiment.

Broader pressure persists across the life sciences tools sector, with Thermo Fisher Scientific down 0.31%, Danaher down 0.29%, Illumina down 1.58%, and Tempus AI down 2.77%.

10x Genomics, Inc. develops instruments, consumables, and software for analyzing biological systems, including single cell and spatial genomics solutions for academic and biopharmaceutical institutions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)